The Global Peptide Market Strategic Intelligence Suite 2026-2031 is the analyst's most comprehensive intelligence offering on the global peptide industry, combining the Peptide Therapy, Peptide API, and Cosmetic Peptides reports (a combined USD 90.3 billion in 2025, growing to over USD 206 billion by 2031) plus a cross-report executive presentation, summary document, and interactive infographic.
The three reports cover sequential and parallel stages of the peptide value chain: Peptide API covers the raw active ingredient manufacturing (USD 5.15B to USD 12.1B, 15.24% CAGR), which feeds into both Peptide Therapy's finished drug products (USD 84.2B to USD 192.1B, 14.74% CAGR, dominated by the GLP-1 revolution) and Cosmetic Peptides' topical formulations (USD 0.95B to USD 2.1B, 13.84% CAGR).
The GLP-1/GIP Receptor Agonist Therapy segment is the single most important structural driver across the suite, accounting for 65.8% of therapy-market value and nearly half of all peptide API revenue by 2031, led by the Novo Nordisk/Eli Lilly duopoly.
The three reports cover sequential and parallel stages of the peptide value chain: Peptide API covers the raw active ingredient manufacturing (USD 5.15B to USD 12.1B, 15.24% CAGR), which feeds into both Peptide Therapy's finished drug products (USD 84.2B to USD 192.1B, 14.74% CAGR, dominated by the GLP-1 revolution) and Cosmetic Peptides' topical formulations (USD 0.95B to USD 2.1B, 13.84% CAGR).
The GLP-1/GIP Receptor Agonist Therapy segment is the single most important structural driver across the suite, accounting for 65.8% of therapy-market value and nearly half of all peptide API revenue by 2031, led by the Novo Nordisk/Eli Lilly duopoly.
Scope of Global Peptide Market Strategic Intelligence Suite 2026-2031
- This Suite includes the complete Global Peptide Therapy Market Strategic Research Report.
- This Suite includes the complete Global Peptide API Market Strategic Research Report.
- This Suite includes the complete Global Cosmetic Peptides Market Strategic Research Report.
- This Suite includes an executive presentation comparing all three reports' key findings.
- This Suite includes a cross-report summary document explaining the peptide value-chain linkage.
- This Suite includes an interactive infographic for board-level and investor-facing use.
Who can use the Global Peptide Market Strategic Intelligence Suite?
This Suite is ideal for people who need the complete peptide value chain in one integrated resource. Some of the intended users are:- Investors evaluating full value-chain exposure across peptide therapeutics, API manufacturing, and cosmetics
- Supply chain executives assessing peptide API capacity and sourcing risk
- C-level executives requiring comprehensive peptide strategic intelligence for board presentations.
Table of Contents
1. Executive Summary2. Industry Overview & Forecast
3. Market Segmentation by Type
4. Market Segmentation by Application
5. Regional Market Forecast
6. Country-Level Market Forecast
7. Growth Drivers & Inhibitors
8. Key Company Profiles
9. Competitive Landscape
10. Porter's Five Forces Analysis
11. PESTLE Analysis
12. SWOT Analysis
13. Future Trends & Outlook
Companies Mentioned
- Novo Nordisk A/S
- Eli Lilly and Company
- Novartis AG
- Ipsen SA
- AbbVie Inc.
- Teva Pharmaceutical Industries
- AstraZeneca plc
- Ferring Pharmaceuticals
- Pfizer Inc.
- Amgen Inc.
- Bachem (Julius Bachem AG)
- PolyPeptide Group
- CordenPharma International
- WuXi STA (WuXi AppTec Peptide)
- Hybio Pharmaceutical
- AmbioPharm Inc.
- ScinoPharm Taiwan
- Almac Group
- Piramal Pharma Solutions
- CPC Scientific Inc.
- GL Biochem (Shanghai) Ltd.
- Croda International
- Lubrizol (Lipotec Active Ingredients)
- Clariant (Lucas Meyer Cosmetics)
- Evonik
- Givaudan
- BASF SE
- Symrise AG
- DSM-Firmenich
- Spec-Chem Industry (China)
